5 References

  • 1
    Di Marzo, V., Matias, I., Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 2005, 8, 585589.
  • 2
    Quarta, C., Mazza, R., Obici, S., Pasquali, R., Pagotto, U., Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol. Med. 2011, 17, 518526.
  • 3
    Matias, I., Petrosino, S., Racioppi, A., Capasso, R. et al., Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol. Cell. Endocrinol. 2008, 286, S66S78.
  • 4
    Matias, I., Gonthier, M. P., Orlando, P., Martiadis, V. et al., Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91, 31713180.
  • 5
    Gasperi, V., Fezza, F., Pasquariello, N., Bari, M. et al., Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell. Mol. Life Sci. 2007, 64, 219229.
  • 6
    Kim, J., Li, Y., Watkins, B. A., Endocannabinoid signaling and energy metabolism: a target for dietary intervention. Nutrition 2011, 27, 624632.
  • 7
    Bouaboula, M., Perrachon, S., Milligan, L., Canat, X. et al., A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 1997, 272, 2233022339.
  • 8
    Watt, M. J., Adipose tissue-skeletal muscle crosstalk: are endocannabinoids an unwanted caller? Diabetologia 2009, 52, 571573.
  • 9
    Colombo, G., Agabio, R., Diaz, G., Lobina, C. et al., Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998, 63, PL113PL117.
  • 10
    Elmquist, J. K., Elias, C. F., Saper, C. B., From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999, 22, 221232.
  • 11
    Cota, D., Marsicano, G., Tschop, M., Grubler, Y. et al., The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 2003, 112, 423431.
  • 12
    Ravinet, T. C., Delgorge, C., Menet, C., Arnone, M., Soubrie, P., CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 640648.
  • 13
    Poirier, B., Bidouard, J. P., Cadrouvele, C., Marniquet, X. et al., The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 2005, 7, 6572.
  • 14
    Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P. et al., The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003, 63, 908914.
  • 15
    Pagano, C., Rossato, M., Vettor, R., Endocannabinoids, adipose tissue and lipid metabolism. J. Neuroendocrinol. 2008, 20 (Suppl 1), 124129.
  • 16
    Girard, J., Perdereau, D., Foufelle, F., Prip-Buus, C., Ferre, P., Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J. 1994, 8, 3642.
  • 17
    Poulos, S. P., Dodson, M. V., Hausman, G. J., Cell line models for differentiation: preadipocytes and adipocytes. Exp. Biol. Med. 2010, 235, 118593.
  • 18
    Green, H., Kehinde, O., Spontaneous heritable changes leading to increased adipose conversion in 3T3 cells. Cell 1976, 7, 105113.
  • 19
    Wang, S., Soni, K. G., Semache, M., Casavant, S. et al., Lipolysis and the integrated physiology of lipid energy metabolism. Mol. Genet. Metab. 2008, 95, 117126.
  • 20
    Baltina, L. A., Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr. Med. Chem. 2003, 10, 15571.
  • 21
    Cho, H. J., Lim, S. S., Lee, Y. S., Kim, J.-S. et al., Hexane/ethanol extract of Glycyrrhiza uralensis licorice exerts potent anti-inflammatory effects in murine macrophages and in mouse skin. Food Chem. 2010, 121, 959966.
  • 22
    Rauchensteiner, F., Matsumura, Y., Yamamoto, Y., Yamaji, S., Tani, T., Analysis and comparison of Radix Glycyrrhizae (licorice) from Europe and China by capillary-zone electrophoresis (CZE). J. Pharm. Biomed. Anal. 2005, 38, 594600.
  • 23
    Montoro, P., Maldini, M., Russo, M., Postorino, S. et al., Metabolic profiling of roots of liquorice (Glycyrrhiza glabra) from different geographical areas by ESI/MS/MS and determination of major metabolites by LC-ESI/MS and LC-ESI/MS/MS. J. Pharm. Biomed. Anal. 2011, 54, 535544.
  • 24
    Kim, H. J., Lim, S. S., Park, I. S., Lim, J. S. et al., Neuroprotective effects of dehydroglyasperin C through activation of heme oxygenase-1 in mouse hippocampal cells. J. Agric. Food Chem. 2012, 60, 55835589.
  • 25
    Mae, T., Kishida, H., Nishiyama, T., Tsukagawa, M. et al., A licorice ethanolic extract with peroxisome proliferator-activated receptor-gamma ligand-binding activity affects diabetes in KK-Ay mice, abdominal obesity in diet-induced obese C57BL mice and hypertension in spontaneously hypertensive rats. J. Nutr. 2003, 133, 33693377.
  • 26
    Moon, M. H., Jeong, J. K., Lee, Y. J., Seol, J. W. et al., 18β-glycyrrhetinic acid inhibits adipogenic differentiation and stimulates lipolysis. Biochem. Biophys. Res. Commun. 2012, 420, 805810.
  • 27
    Eisenbrand, G., Glycyrrhizin. Mol. Nutr. Food Res. 2006, 50, 10871088.
  • 28
    Visavadiya, N. P., Narasimhacharya, A. V., Hypocholesterolaemic and antioxidant effects of Glycyrrhiza glabra (Linn) in rats. Mol. Nutr. Food Res. 2006, 50, 10801086
  • 29
    Classen-Houben, D., Schuster, D., Da Cunha, T., Odermatt, A. et al., Selective inhibition of 11β-hydroxysteroid dehydrogenase 1 by 18α-glycyrrhetinic acid but not 18β-glycyrrhetinic acid. J. Steroid Biochem. Mol. Biol. 2009, 113, 248252.
  • 30
    D'Eon, T. M., Pierce, K. A., Roix, J. J., Tyler, A. et al., The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008, 57, 12621268
  • 31
    Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L. et al., Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 2005, 517, 174181
  • 32
    Childers, S. R., Pacheco, M. A., Bennett, B. A., Edwards, T. A. et al., Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 1993, 59, 2750.
  • 33
    Vettor, R., Pagano, C., The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 5163.
  • 34
    Graugnard, D. E., Piantoni, P., Bionaz, M., Berger, L. L. et al., Adipogenic and energy metabolism gene networks in longissimus lumborum during rapid post-weaning growth in Angus and Angus × Simmental cattle fed high-starch or low-starch diets. BMC Genomics 2009, 10, 142.
  • 35
    Bellocchio, L., Cervino, C., Vicennati, V., Pasquali, R., Pagotto, U., Cannabinoid type 1 receptor: another arrow in the adipocytes’ bow. J. Neuroendocrinol. 2008, 20(Suppl 1), 130138.
  • 36
    Herling, A. W., Kilp, S., Elvert, R., Haschke, G., Kramer, W., Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008, 149, 25572566.
  • 37
    Bosier, B., Muccioli, G. G., Hermans, E., Lambert, D. M., Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem. Pharmacol. 2010, 80, 112.
  • 38
    Karaliota, S., Siafaka-Kapadai, A., Gontinou, C., Psarra, K. et al., Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation. Obesity 2009, 17, 18301838.
  • 39
    Jourdan, T., Djaouti, L., Demizieux, L., Gresti, J. et al., CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010, 59, 926934
  • 40
    Eckardt, K., Sell, H., Taube, A., Koenen, M. et al., Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009, 52(4), 664674.
  • 41
    Tam, J., Vemuri, V. K., Liu, J., Batkai, S. et al., Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest. 2010, 120(8), 29532966
  • 42
    Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J. et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115, 12981305.
  • 43
    Kyrou, I., Valsamakis, G., Tsigos, C., The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann. N. Y. Acad. Sci. 2006, 1083, 270305.
  • 44
    Kunos, G., Osei-Hyiaman, D., Liu, J., Godlewski, G., Batkai, S., Endocannabinoids and the control of energy homeostasis. J. Biol. Chem. 2008, 283, 3302133025.
  • 45
    Monsif, B., Sandrine, H., Jean, M., Lluis, F. et al., Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 2005, 517, 174181.
  • 46
    Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., Astrup, Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370, 17061713.
  • 47
    Van Gaal, L., Pi-Sunyer, X., Despres, J. P., McCarthy, C. et al., Efficacy and safety of rimonabant for improvement of multiple cardimetabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31, S229S240.
  • 48
    Nathan, P. J., O'Neil, B. V., Napolitano, A., Bullmore, E. T., Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neruosci. Ther. 2011, 17, 490505.
  • 49
    Clark, D. E., In silico prediction of blood-brain barrier permeation. Drug Discov. Today 2003, 8, 927933.
  • 50
    Christopoulou, F. D., Kiortsis, D. N., An overview of the metabolic effects of rimonabant in randomized controlled trials: Potential for other cannabinoid 1 receptor blockers in obesity. J. Clin. Pharm. Ther. 2011, 36, 1018.
  • 51
    Kirilly, E., Gonda, X., Bagdy, G., CB1 receptor antagonists: New discoveries leading to new perspectives. Acta Physiol. 2012, 205, 4160.
  • 52
    Serra, A., Uehlinger, D. E., Ferrari, P., Dick, B. et al., Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. J. Am. Soc. Nephrol. 2002, 13(1), 191196.
  • 53
    Stormer, F. C., Reistad, R., Alexander, J., Glycyrrhizic acid in liquorice-evaluation of health hazard. Food. Chem. Toxicol. 1993, 31(4), 303312.